CARMENA in mRCC and Surgical Management Cases in Bladder Cancer from ASCO 2018 - Tom Keane

June 23, 2018

(Length of Discussion: 30 min)

Tom Keane, MBBCh, FRCSI, FACS provides a detailed overview of the CARMENA study, presented by Arnaud Mejean MD, Ph.D. at ASCO 2018.  This Phase III randomized trial assessed the utility and timing of CNx in the treatment paradigm of mRCC comparing patients who were randomized to either CNx and sunitinib vs sunitinib alone without CNx.  He discusses the clinical application of the findings of CARMENA as well as comparing the results with that of another study, SURTIME, an EROTC presented at EUA 2018.

Next, Tom Keane reviews Dr. Gary Sternberg’s ASCO 2018 presentation of Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer. In this multi-disciplinary session focused on bladder cancer, 3 specific patient cases were addressed.  He begins with an overview of the initial patient presentation and moves through each case highlighting the surgical management options for each. 

Biographies:

Thomas E. Keane, MBBCh, FRCSI, FACS